Nuvation Bio Inc
For the period ended Jun 30, 2024. Filed Aug 5, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 5, 2024
NUVB$4.20-3.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Cash Flows
(Unaudited, In thousands)
| For the Six Months Ended June 30, | 2024 | 2023 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net loss | $(477,284) | $(42,366) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 14,610 | 10,360 |
| Depreciation and amortization | 302 | 112 |
| Non-cash lease expense | (77) | (35) |
| Change in fair value of warrant liability | 324 | 123 |
| Amortization of premium on marketable securities | (5,244) | (5,368) |
| Realized loss on marketable securities | 6 | 195 |
| Net loss on disposal of property and equipment | — | 12 |
| Acquired in-process research and development | 425,070 | — |
| Change in operating assets and liabilities: | ||
| Accounts receivable | (117) | — |
| Prepaid expenses and other current assets | (1,731) | 288 |
| Interest receivable on marketable securities | (192) | (310) |
| Lease security deposit | (2) | — |
| Other non-current assets | (488) | — |
| Accounts payable | (2,791) | 438 |
| Contract liabilities | (1,391) | — |
| Accrued expenses | (4,022) | (264) |
| Net cash used in operating activities | (53,026) | (36,815) |
| Cash flow from investing activities: | ||
| Cash acquired from AnHeart acquisition | 19,863 | — |
| Transaction costs related to AnHeart acquisition | (7,343) | — |
| Purchases of marketable securities | (221,939) | (443,800) |
| Proceeds from sale of marketable securities | 251,261 | 429,184 |
| Purchases of property and equipment | (27) | (34) |
| Net cash provided by (used in) investing activities | 41,815 | (14,650) |
| Cash flow from financing activities: | ||
| Proceeds from borrowings | 7,035 | — |
| Payments on borrowings | (6,322) | — |
| Proceeds from issuance of Common Stock under ESPP | 108 | 133 |
| Proceeds from exercises of options | 1,948 | 298 |
| Net cash provided by financing activities | 2,769 | 431 |
| Effect of foreign exchange rate changes on cash and cash equivalents | 78 | — |
| Net decrease in cash and cash equivalents | (8,364) | (51,034) |
| Cash and cash equivalents, beginning of the period | 42,649 | 101,099 |
| Cash and cash equivalents, end of the period | $34,285 | $50,065 |
| Non-cash investing activities: | ||
| Issuance of Common Stock related to the AnHeart acquisition | $89,297 | $— |
| Issuance of convertible preferred stock related to the AnHeart acquisition | $274,938 | $— |
| Issuance of warrants related to the AnHeart acquisition | $764 | $— |
| Issuance of replacement awards related to the AnHeart acquisition | $24,818 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.